CN116421635A - Low-irritation antipruritic ball formula and preparation method thereof - Google Patents
Low-irritation antipruritic ball formula and preparation method thereof Download PDFInfo
- Publication number
- CN116421635A CN116421635A CN202310472029.9A CN202310472029A CN116421635A CN 116421635 A CN116421635 A CN 116421635A CN 202310472029 A CN202310472029 A CN 202310472029A CN 116421635 A CN116421635 A CN 116421635A
- Authority
- CN
- China
- Prior art keywords
- irritation
- parts
- low
- antipruritic
- ball
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001139 anti-pruritic effect Effects 0.000 title claims abstract description 21
- 239000003908 antipruritic agent Substances 0.000 title claims abstract description 21
- 238000009472 formulation Methods 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title abstract description 9
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 24
- FDVCQFAKOKLXGE-UHFFFAOYSA-N 216978-79-9 Chemical compound C1CC(C)(C)C2=CC(C=O)=CC3=C2N1CCC3(C)C FDVCQFAKOKLXGE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 12
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 12
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 12
- 239000003906 humectant Substances 0.000 claims abstract description 12
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 12
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 12
- 229940068977 polysorbate 20 Drugs 0.000 claims abstract description 12
- 229940016667 resveratrol Drugs 0.000 claims abstract description 12
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 12
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 12
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 9
- 239000000314 lubricant Substances 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 229940083037 simethicone Drugs 0.000 claims description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 1
- 230000007794 irritation Effects 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229920002545 silicone oil Polymers 0.000 description 5
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000011201 Ginkgo Nutrition 0.000 description 3
- 241000218628 Ginkgo Species 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A low-irritation antipruritic ball formula and a preparation method thereof, wherein the formula comprises the following substances in parts by weight: salicylic acid: 0.5-1 part; humectant: 25-35 parts of a lubricant; resveratrol: 0.1-0.2 part; polysorbate 20:3-7 parts; propyl oleate: 3-5 parts; ginkgo leaf extract: 1-2 parts, the formula and the concentration are controlled, the low irritation is ensured, the drug effect is ensured, the raw materials are cheap, the processing engineering is simple, and the production cost is reduced.
Description
Technical Field
The invention relates to the technical field of antipruritic balls, in particular to a low-irritation antipruritic ball formula and a preparation method thereof.
Background
Problems with low irritation rollerball formulations include the following:
the effect is not good: in order to reduce skin irritation, low irritation rollerball often requires the use of mild ingredients, which may compromise sweat absorption and sweat malodour prevention effects, resulting in discomfort to the user.
The cost is higher: in order to meet the requirement of low irritation, the low irritation ball needs to use higher-grade raw materials, which results in higher cost of the product, thereby limiting the popularization and promotion of the product.
Disclosure of Invention
In view of the shortcomings of the background technology, the invention provides a low-irritation antipruritic ball formula, which solves the problems of the existing ball formula that the effect is not good and the cost is high.
The invention relates to a low-irritation antipruritic ball formula which comprises the following substances in parts by weight:
salicylic acid: 0.5-1 part;
humectant: 25-35 parts of a lubricant;
resveratrol: 0.1-0.2 part;
polysorbate 20:3-7 parts;
propyl oleate: 3-5 parts;
ginkgo leaf extract: 1-2 parts.
Further, the formula comprises salicylic acid, humectant, resveratrol, polysorbate 20, propyl oleate, ginkgo leaf extract and distilled water.
Further, the method also comprises the following steps of: 4 parts.
Further, the silicone oil also comprises dimethyl silicone oil: 3 parts.
Further, the humectant is propylene glycol or glycerol.
The invention also provides a preparation method of the low-irritation antipruritic ball formula, which adopts the low-irritation antipruritic ball formula and specifically comprises the following steps:
s1, uniformly mixing salicylic acid, a humectant, resveratrol, polysorbate 20 and propyl oleate according to a proportion;
s2, adding water in a corresponding proportion, and continuously stirring to form a uniformly mixed emulsion with the concentration of 15-20%;
s3, gradually adding the ginkgo leaf extract, and uniformly stirring to obtain a concentrated solution;
s4, adding distilled water, and adjusting the concentration to 10+/-1%.
Further, in the step S1, in the mixing process, the aluminum hydroxide prepared according to the proportion is added and uniformly mixed.
Further, after the step S3, dimethyl silicone oil is added into the concentrated solution and stirred uniformly.
The invention has the main beneficial effects that:
1. the formula and the concentration are controlled, so that the low irritation is ensured, and the drug effect is ensured;
2. the raw materials are cheap, the processing engineering is simple, and the production cost is reduced.
Detailed Description
It is apparent that what is described herein is only a part, but not all, of the examples of the present invention, and that all other embodiments, which can be obtained by those skilled in the art without making any inventive effort, are within the scope of the present invention.
In order to facilitate an understanding of embodiments of the present invention, a further explanation will be made below by taking specific embodiments as examples, and the respective embodiments do not constitute a limitation of the embodiments of the present invention.
The embodiment 1 of the invention relates to a low-irritation antipruritic ball formula, which comprises the following substances in parts by weight:
salicylic acid: 0.5-1 part;
humectant: 25-35 parts of a lubricant;
resveratrol: 0.1-0.2 part;
polysorbate 20:3-7 parts;
propyl oleate: 3-5 parts;
ginkgo leaf extract: 1-2 parts.
Wherein aluminum hydroxide can be added into the formula: 4 parts.
Wherein, the formula can also be added with simethicone: 3 parts.
The humectant is propylene glycol or glycerol.
The invention also provides a preparation method of the low-irritation antipruritic ball formula, which adopts the low-irritation antipruritic ball formula and specifically comprises the following steps:
s1, uniformly mixing salicylic acid, a humectant, resveratrol, polysorbate 20 and propyl oleate according to a proportion;
s2, adding water in a corresponding proportion, and continuously stirring to form a uniformly mixed emulsion with the concentration of 15-20%;
s3, gradually adding the ginkgo leaf extract, and uniformly stirring to obtain a concentrated solution;
s4, adding distilled water, and adjusting the concentration to 10+/-1%.
When aluminum hydroxide is added into the formula, in the step S1, the aluminum hydroxide prepared according to the proportion is added and uniformly mixed in the mixing process.
When the dimethyl silicone oil is added into the formula, after the step S3, the dimethyl silicone oil is added into the concentrated solution and stirred uniformly.
Example 2 of the present invention relates to a comparison of the effect of the ball formulation:
experiment design:
40 mice of 8 weeks of age were selected, of which 20 males, 20 females, the weight of the males being 23 g.+ -.1 g, and the weight of the females being 20 g.+ -.1 g, were randomly divided into 4 groups of 5 males and 5 females. Prior to modeling, basal levels of mouse skin electrical activity were measured using a skin electrical activity measuring instrument and recorded.
Then injecting the same amount of histamine into the mice, and after waiting for 10 minutes, respectively smearing A, B, C, D four groups of formulas on four groups of mice for real-time monitoring of skin electric activity.
Wherein, the four formulas of A, B, C, D are respectively:
group A: propylene glycol at a concentration of 10% was used as a control group;
group B: 1 part of salicylic acid, 35 parts of propylene glycol, 0.1 part of resveratrol, 5 parts of polysorbate 20, 5 parts of propyl oleate and 1 part of ginkgo extract, and the formula prepared by the preparation method in the example 1;
group C: 1 part of salicylic acid, 4 parts of aluminum hydroxide, 35 parts of propylene glycol, 0.1 part of resveratrol, 5 parts of polysorbate 20, 5 parts of propyl oleate and 1 part of ginkgo extract, and the formula prepared by adopting the preparation method in the example 1;
group D: 1 part of salicylic acid, 35 parts of propylene glycol, 0.1 part of resveratrol, 5 parts of polysorbate 20, 5 parts of propyl oleate, 1 part of ginkgo extract and 3 parts of simethicone, and the formula prepared by the preparation method in the example 1 is adopted.
Experimental records:
the average change in the skin electrical activity (μv) of the mice was recorded at 30 seconds as nodes.
Table 1, skin spot activity float value control table for each group of mice:
conclusion: at 0S, the skin electric activity value of the mice is improved due to the fact that 4 groups of formulas are just smeared, but the skin electric activity of the mice gradually returns to a normal value along with the time, wherein the change value of female mice and male mice in the same group is not greatly different in the experiment, the itching relieving effect of group 3 mice using the group C drugs is optimal, the skin electric activity of the mice in 3 minutes returns to the normal value, the irritation of the mice in the group D drugs is minimum, and the skin electric activity of the mice in the group B drugs and the skin electric activity of the mice in the group D drugs both return to the normal value in 3.5 minutes, which is far better than that of the drugs which play a role in five minutes on the market.
Finally, it should be noted that: the above examples are only specific embodiments of the present invention, and are not intended to limit the scope of the present invention, but it should be understood by those skilled in the art that the present invention is not limited thereto, and that the present invention is described in detail with reference to the foregoing examples: any person skilled in the art may modify or easily conceive of the technical solution described in the foregoing embodiments, or perform equivalent substitution of some of the technical features, while remaining within the technical scope of the present disclosure; such modifications, changes or substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention, and are intended to be included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (8)
1. The low-irritation antipruritic ball formula is characterized by comprising the following substances in parts by weight:
salicylic acid: 0.5-1 part;
humectant: 25-35 parts of a lubricant;
resveratrol: 0.1-0.2 part;
polysorbate 20:3-7 parts;
propyl oleate: 3-5 parts;
ginkgo leaf extract: 1-2 parts.
2. The low-irritation antipruritic ball formulation of claim 1, wherein: the formula consists of salicylic acid, humectant, resveratrol, polysorbate 20, propyl oleate, ginkgo leaf extract and distilled water.
3. The low-irritation antipruritic ball formulation of claim 1, wherein: further comprising aluminum hydroxide: 4 parts.
4. The low-irritation antipruritic ball formulation of claim 1, wherein: also included are dimethicones: 3 parts.
5. The low-irritation antipruritic ball formulation of claim 1, wherein: the humectant is propylene glycol or glycerol.
6. A method for preparing a low-irritation antipruritic ball formulation, characterized in that a low-irritation antipruritic ball formulation according to any one of claims 1-5 is used, comprising the steps of:
s1, uniformly mixing salicylic acid, a humectant, resveratrol, polysorbate 20 and propyl oleate according to a proportion;
s2, adding water in a corresponding proportion, and continuously stirring to form a uniformly mixed emulsion with the concentration of 15-20%;
s3, gradually adding the ginkgo leaf extract, and uniformly stirring to obtain a concentrated solution;
s4, adding distilled water, and adjusting the concentration to 10+/-1%.
7. The low-irritation antipruritic ball formulation of claim 6, wherein: and S1, adding the aluminum hydroxide prepared according to the proportion in the mixing process, and uniformly mixing.
8. The low-irritation antipruritic ball formulation of claim 6, wherein: and S3, adding the simethicone into the concentrated solution, and uniformly stirring.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310472029.9A CN116421635A (en) | 2023-04-27 | 2023-04-27 | Low-irritation antipruritic ball formula and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310472029.9A CN116421635A (en) | 2023-04-27 | 2023-04-27 | Low-irritation antipruritic ball formula and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116421635A true CN116421635A (en) | 2023-07-14 |
Family
ID=87085393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310472029.9A Pending CN116421635A (en) | 2023-04-27 | 2023-04-27 | Low-irritation antipruritic ball formula and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116421635A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009084020A2 (en) * | 2007-10-18 | 2009-07-09 | Glenmark Pharmaceuticals Limited | Topical composition comprising halobetasol and salicylic acid |
| CN101690700A (en) * | 2009-09-29 | 2010-04-07 | 广东名臣有限公司 | Cooling and antipruritic toilet water |
| CN104800715A (en) * | 2015-04-25 | 2015-07-29 | 深圳市新华南方生物科技股份有限公司 | Formula and preparation method of skincare itching relieving spray |
| WO2017080049A1 (en) * | 2015-11-13 | 2017-05-18 | 谭惠娟 | Antipruritic ointment and method for preparing same |
| CN109288758A (en) * | 2018-11-22 | 2019-02-01 | 林锡慧 | A kind of mosquito-expelling and antipruritic formula of sun screen |
| CN110339075A (en) * | 2019-06-17 | 2019-10-18 | 重庆中妆科技有限公司 | A kind of Antiperspirant dew production formula having no irritating odor |
| CN111686046A (en) * | 2020-06-15 | 2020-09-22 | 株洲千金药业股份有限公司 | Refreshing and consciousness restoring bead composition, bead and preparation method |
| CN111821331A (en) * | 2020-07-21 | 2020-10-27 | 昆明医科大学 | External gel for repelling mosquitoes, relieving itching and diminishing swelling and preparation method thereof |
| CN113244382A (en) * | 2021-06-11 | 2021-08-13 | 江南大学 | Itching-relieving and swelling-diminishing composition as well as preparation method and application thereof |
-
2023
- 2023-04-27 CN CN202310472029.9A patent/CN116421635A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009084020A2 (en) * | 2007-10-18 | 2009-07-09 | Glenmark Pharmaceuticals Limited | Topical composition comprising halobetasol and salicylic acid |
| CN101690700A (en) * | 2009-09-29 | 2010-04-07 | 广东名臣有限公司 | Cooling and antipruritic toilet water |
| CN104800715A (en) * | 2015-04-25 | 2015-07-29 | 深圳市新华南方生物科技股份有限公司 | Formula and preparation method of skincare itching relieving spray |
| WO2017080049A1 (en) * | 2015-11-13 | 2017-05-18 | 谭惠娟 | Antipruritic ointment and method for preparing same |
| CN109288758A (en) * | 2018-11-22 | 2019-02-01 | 林锡慧 | A kind of mosquito-expelling and antipruritic formula of sun screen |
| CN110339075A (en) * | 2019-06-17 | 2019-10-18 | 重庆中妆科技有限公司 | A kind of Antiperspirant dew production formula having no irritating odor |
| CN111686046A (en) * | 2020-06-15 | 2020-09-22 | 株洲千金药业股份有限公司 | Refreshing and consciousness restoring bead composition, bead and preparation method |
| CN111821331A (en) * | 2020-07-21 | 2020-10-27 | 昆明医科大学 | External gel for repelling mosquitoes, relieving itching and diminishing swelling and preparation method thereof |
| CN113244382A (en) * | 2021-06-11 | 2021-08-13 | 江南大学 | Itching-relieving and swelling-diminishing composition as well as preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 曾斌;等: "消炎止痒喷雾剂毒理学实验研究", 中国医药导报, vol. 5, no. 32, 15 November 2008 (2008-11-15), pages 12 - 13 * |
| 赵晶;等: "水杨酸微乳的制备及其体外透皮吸收研究", 中国药房, vol. 26, no. 01, 10 January 2015 (2015-01-10) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108992451A (en) | A kind of emulsifiable paste and preparation method thereof with anti-inflammatory anti-itch antibiotic effect | |
| CN106619489A (en) | Temperature-sensitive gel for skin injury and preparation method of temperature-sensitive gel | |
| White et al. | Physiological and pharmacological regulation of human salivary electrolyte concentrations; with a discussion of electrolyte concentrations of some other exocrine secretions | |
| CN116807924A (en) | Collagen-containing skin anti-wrinkle composition, anti-wrinkle product and preparation method thereof | |
| CN102670456A (en) | Multi-effect facial cream and preparation method thereof | |
| CN114366678A (en) | Liquid skin-care cream and preparation method thereof | |
| CN108096095A (en) | A kind of composite whitening and composition and its application for soothing the skin stimulatory function | |
| CN110339102A (en) | Marine algae extract composition and its purposes in cosmetics | |
| CN116421635A (en) | Low-irritation antipruritic ball formula and preparation method thereof | |
| CN112773733A (en) | Acne-removing composition and preparation method of emulsion thereof | |
| CN108904340B (en) | Seaweed composition with oil control effect and cosmetic thereof | |
| CN111568778A (en) | Three-layer essence with skin color modification and skin nourishing effects, and preparation method and application thereof | |
| CN107557190A (en) | A kind of 3D printing handmade soap and preparation method thereof | |
| EP3932487A1 (en) | External preparation for vascular abnormality treatment | |
| Bénéfice et al. | Growth and maturation of Sereer adolescent girls (Senegal) in relation to seasonal migration for labor | |
| KR102096743B1 (en) | Cosmetic Compositions for Skin Moisturizing | |
| DE69821240T2 (en) | PHOSPHATIC ACID COMPOSITIONS AS IMMUNOMODULATORS | |
| CN112263492A (en) | Formula of jelly-like suspended oil drop high-moisture sleeping mask and preparation process thereof | |
| CN109394632B (en) | Allergy-relieving moisturizing lotion and preparation method thereof | |
| CN100563683C (en) | A kind of external preparation for the treatment of skin amyloidosis | |
| JP5422956B2 (en) | Cream for external use of skin | |
| CN107998041A (en) | A kind of bacteriostatic skin-care product containing a thousand pieces of gold boisiana extract | |
| CN113476370B (en) | Skin care composition and preparation method thereof | |
| CN108938502A (en) | A kind of edible crystal mask and preparation method thereof | |
| CN116421486B (en) | Emulsifier composition, emulsified toning lotion and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |